Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 268

1.

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE.

J Gastrointest Surg. 2017 Jan;21(1):164-174. doi: 10.1007/s11605-016-3265-1. Epub 2016 Oct 24.

PMID:
27778257
2.

Regionalization Does Not Equal Integration.

Brown AD, Pisters PW, Naylor CD.

Healthc Pap. 2016;16(1):4-6. No abstract available.

PMID:
27734783
3.

Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial.

Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, Peters WR Jr, Maun D, Chang G, Herline A, Fichera A, Mutch M, Wexner S, Whiteford M, Marks J, Birnbaum E, Margolin D, Larson D, Marcello P, Posner M, Read T, Monson J, Wren SM, Pisters PW, Nelson H.

JAMA. 2015 Oct 6;314(13):1346-55. doi: 10.1001/jama.2015.10529.

4.

Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.

Liu L, Katz MH, Lee SM, Fischer LK, Prakash L, Parker N, Wang H, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Maitra A, Fleming JB, Estrella J, Rashid A, Wang H.

Am J Surg Pathol. 2015 Oct;39(10):1395-403. doi: 10.1097/PAS.0000000000000491.

PMID:
26200098
5.

Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma.

Tseng WW, Zhou S, To CA, Thall PF, Lazar AJ, Pollock RE, Lin PP, Cormier JN, Lewis VO, Feig BW, Hunt KK, Ballo MT, Patel S, Pisters PW.

Cancer. 2015 Oct 15;121(20):3659-67. doi: 10.1002/cncr.29544. Epub 2015 Jul 15.

6.

Multicystic dedifferentiated retroperitoneal liposarcoma: tumour cyst fluid analysis and implications for management.

Khoury M, Sim GC, Harao M, Radvanyi L, Amini B, Benjamin RS, Pisters PW, Pollock RE, Tseng WW.

BMJ Case Rep. 2015 Jul 8;2015. pii: bcr2015211218. doi: 10.1136/bcr-2015-211218.

PMID:
26156843
7.

Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.

Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB.

Ann Surg Oncol. 2015 Apr;22(4):1168-75. doi: 10.1245/s10434-014-4192-6. Epub 2014 Oct 29.

8.

Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection?

Tseng WW, Madewell JE, Wei W, Somaiah N, Lazar AJ, Ghadimi MP, Hoffman A, Pisters PW, Lev DC, Pollock RE.

Ann Surg Oncol. 2014 Jul;21(7):2136-43. doi: 10.1245/s10434-014-3643-4. Epub 2014 Apr 7.

PMID:
24705628
9.

Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors.

Bednarski BK, Araujo DM, Yi M, Torres KE, Lazar A, Trent JC, Cormier JN, Pisters PW, Lev DC, Pollock RE, Feig BW, Hunt KK.

Ann Surg Oncol. 2014 Aug;21(8):2499-505. doi: 10.1245/s10434-014-3632-7. Epub 2014 Mar 18.

10.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP.

J Clin Oncol. 2014 May 20;32(15):1563-70. doi: 10.1200/JCO.2013.51.2046. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Oct 20;32(30):3462.

11.

Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.

Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH.

J Gastrointest Surg. 2014 Jan;18(1):16-24; discussion 24-5. doi: 10.1007/s11605-013-2412-1. Epub 2013 Nov 16.

PMID:
24241967
12.

Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer.

Tran Cao HS, Balachandran A, Wang H, Nogueras-González GM, Bailey CE, Lee JE, Pisters PW, Evans DB, Varadhachary G, Crane CH, Aloia TA, Vauthey JN, Fleming JB, Katz MH.

J Gastrointest Surg. 2014 Feb;18(2):269-78; discussion 278. doi: 10.1007/s11605-013-2374-3. Epub 2013 Oct 16.

13.

Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification.

Tzeng CW, Katz MH, Fleming JB, Lee JE, Pisters PW, Holmes HM, Varadhachary GR, Wolff RA, Abbruzzese JL, Vauthey JN, Aloia TA.

J Gastrointest Surg. 2014 Jan;18(1):146-55; discussion 155-6. doi: 10.1007/s11605-013-2371-6. Epub 2013 Oct 16.

PMID:
24129825
14.

Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.

Chatterjee D, Katz MH, Rashid A, Estrella JS, Wang H, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB, Wang H.

Histopathology. 2013 Dec;63(6):841-51. doi: 10.1111/his.12234. Epub 2013 Sep 20.

15.

Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.

Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, Aloia TA, Vauthey JN, Fleming JB, Katz MH.

HPB (Oxford). 2014 May;16(5):430-8. doi: 10.1111/hpb.12154. Epub 2013 Aug 29.

16.

Quality assessment across a national cancer network.

Simeone WJ Jr, Bingham J, Burke TW, Pisters PW.

J Oncol Pract. 2013 May;9(3):165-8. doi: 10.1200/JOP.2013.001048. Review.

17.

Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients.

Tzeng CW, Katz MH, Lee JE, Fleming JB, Pisters PW, Vauthey JN, Aloia TA.

HPB (Oxford). 2014 Apr;16(4):373-83. doi: 10.1111/hpb.12148. Epub 2013 Jul 22.

18.

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.

DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.

Ann Surg. 2013 Sep;258(3):422-9. doi: 10.1097/SLA.0b013e3182a15eb7.

19.

Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA.

Ann Surg Oncol. 2013 Aug;20(8):2787-95. doi: 10.1245/s10434-013-2886-9. Epub 2013 Feb 23. Review.

PMID:
23435609
20.

Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.

Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW, Varadhachary GR, Abbruzzese JL, Wolff RA, Ahmad SA, Katz MH.

Ann Surg Oncol. 2013 Jul;20(7):2197-203. doi: 10.1245/s10434-013-2889-6. Epub 2013 Feb 14.

PMID:
23408126

Supplemental Content

Loading ...
Support Center